AIIB approves 260-mln-USD loan for Bangladesh s steel bridge Xinhua | Updated: 2021-05-25 17:03
DHAKA The Asian Infrastructure Investment Bank (AIIB) has approved a 260-million-US dollar loan to Bangladesh for the construction of the country s first arch steel bridge.
The Kewatkhali Bridge will substantially ease congestion in the northern city of Mymensingh by diverting traffic from the busy city center, the Beijing-based lender said in a statement posted on Tuesday.
Moreover, it said the new bridge will be part of the Dhaka-Mymensingh-India border corridor, which is strategically important for local and regional connectivity.
Once completed, according to AIIB, over 11 million people in Bangladesh s northern region will benefit from increased mobility and integration of local and regional markets.
Why Indonesia s new Bali is accused of trampling on human rights yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Originally adopted in February 2016, the ESF serves as the cornerstone to support environmentally and socially sustainable infrastructure projects for AIIB s clients
How China-led AIIB can expand its remit to build a greener, more inclusive post-pandemic world
The recovery-boosting infrastructure spending sprees favoured by developed nations are out of reach for less-well-off countries that need them most
The AIIB has the scope and track record to expand to a global level and help those nations left behind
Message :
Required fields 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study OCREVUS-treated patients show highest adherence and persistence rates compared with other disease-modifying therapies (DMTs) in two-year U.S. claims analysis Basel, 16 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today
announced new OCREVUS(R) (ocrelizumab) analyses supporting its
significant benefit on disease progression in early-stage
relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS